FDA’s View on Postmarket Drug Safety

FDA and Medscape series for healthcare professionals

The interview features Gerald Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research FDA. Dr. Pan responds to questions from Medscape to detail the FDA’s outlook on postmarket drug safety. The article is part of a collaboration between FDA and Medscape, which launched the series of interviews  and commentaries on wide-ranging topics to communicate important safety information to clinicians.



Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: